Gastroenterology

Daily aspirin may reduce HBV-related hepatocellular carcinoma risk




The risk for hepatocellular carcinoma was statistically significantly reduced by 29% in patients with hepatitis B virus who received daily aspirin, according to findings published in JAMA Internal Medicine.
“Antiviral therapy cannot erase hepatocellular carcinoma (HCC) risk in patients with chronic hepatitis B, and it is not indicated for most hepatitis B virus (HBV) carriers,” Teng-Yu Lee, MD, MBA, PhD, from the division of gastroenterology and hepatology at the Taichung Veterans General Hospital, Taiwan, and colleagues wrote. “Another effective way of reducing HCC risk

Source link




Related posts

Post-Endoscopic Infection More Common Than Previously Thought

Newsemia

What You Can Do About Heartburn

Newsemia

P164 EPITHELIAL TLR4-INDUCED DYSBIOSIS INCREASES SUSCEPTIBILITY TO TUMORIGENESIS

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy